[go: up one dir, main page]

PL3848361T3 - Sposób wytwarzania związku tetracyklicznego - Google Patents

Sposób wytwarzania związku tetracyklicznego

Info

Publication number
PL3848361T3
PL3848361T3 PL19856540.0T PL19856540T PL3848361T3 PL 3848361 T3 PL3848361 T3 PL 3848361T3 PL 19856540 T PL19856540 T PL 19856540T PL 3848361 T3 PL3848361 T3 PL 3848361T3
Authority
PL
Poland
Prior art keywords
manufacturing
tetracyclic compound
tetracyclic
compound
Prior art date
Application number
PL19856540.0T
Other languages
English (en)
Inventor
Hiroki SERIZAWA
Akira Kawase
Hiroshi Fukuda
Naoto Hama
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of PL3848361T3 publication Critical patent/PL3848361T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B61/00Other general methods
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL19856540.0T 2018-09-04 2019-09-03 Sposób wytwarzania związku tetracyklicznego PL3848361T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018165313 2018-09-04
PCT/JP2019/034543 WO2020050241A1 (ja) 2018-09-04 2019-09-03 4環性化合物の製造方法

Publications (1)

Publication Number Publication Date
PL3848361T3 true PL3848361T3 (pl) 2025-07-07

Family

ID=69722303

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19856540.0T PL3848361T3 (pl) 2018-09-04 2019-09-03 Sposób wytwarzania związku tetracyklicznego

Country Status (18)

Country Link
US (1) US11939322B2 (pl)
EP (1) EP3848361B1 (pl)
JP (1) JP7167171B2 (pl)
KR (1) KR102635225B1 (pl)
CN (1) CN112585126B (pl)
AR (1) AR116113A1 (pl)
AU (1) AU2019337018B2 (pl)
BR (1) BR112021001145A2 (pl)
CA (1) CA3107270A1 (pl)
ES (1) ES3010145T3 (pl)
HR (1) HRP20250284T1 (pl)
HU (1) HUE070227T2 (pl)
IL (1) IL281079B2 (pl)
MX (1) MX2021002311A (pl)
PL (1) PL3848361T3 (pl)
SG (1) SG11202100983XA (pl)
TW (1) TWI825163B (pl)
WO (1) WO2020050241A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202245785A (zh) 2021-01-29 2022-12-01 日商中外製藥股份有限公司 兒童癌症治療用之醫藥組成物
CN117024410A (zh) * 2023-08-15 2023-11-10 上海药坦药物研究开发有限公司 一种艾乐替尼中间体及其制备方法
WO2025067412A1 (zh) * 2023-09-28 2025-04-03 重庆博腾制药科技股份有限公司 一种抗肿瘤药物中间体的制备方法
CN120081779A (zh) * 2025-02-19 2025-06-03 江苏天士力帝益药业有限公司 一种阿来替尼杂质01a及其控制方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS506987B1 (pl) 1970-02-17 1975-03-19
JPS4918630B1 (pl) 1970-07-29 1974-05-11
JPS5859712U (ja) 1981-10-16 1983-04-22 ニチバン株式会社 ラベル貼付機
JPH0892090A (ja) 1994-07-26 1996-04-09 Tanabe Seiyaku Co Ltd 医薬組成物
EP0695755B1 (en) 1994-08-04 1998-10-21 F. Hoffmann-La Roche AG Pyrrolocarbazole
US5936084A (en) 1996-05-01 1999-08-10 Eli Lilly And Company Halo-substituted bisindolemaleimide protein kinase C inhibitors
BR9917112A (pt) 1998-12-24 2002-01-29 Fujisawa Pharmaceutical Co Compostos de imidazol e seu uso medicinal
US6632822B1 (en) 1999-05-14 2003-10-14 The Australian National University Compounds and therapeutic methods
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
FR2841138B1 (fr) 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
CN100398519C (zh) 2003-02-28 2008-07-02 伊诺泰克制药公司 四环苯甲酰胺衍生物及其用法
SI1454992T1 (sl) 2003-03-07 2006-10-31 Ist Naz Stud Cura Dei Tumori Test kinaze anaplasticnega limfoma, reagenti in sestavki le-teh
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US7378414B2 (en) 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
RU2006121646A (ru) 2003-11-21 2008-01-10 Новартис АГ (CH) Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы
WO2005056529A1 (en) 2003-12-12 2005-06-23 Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors
US7868036B2 (en) 2004-03-19 2011-01-11 Novartis Ag Organic compounds
US20090155903A1 (en) 2004-03-19 2009-06-18 Myriad Genetics, Incorporated Pharmaceutical composition and method
EP1730128A1 (en) 2004-03-31 2006-12-13 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
AU2005252214A1 (en) 2004-06-02 2005-12-22 Pharmacyclics, Inc Factor VIIa inhibitor
MX2007002312A (es) 2004-08-26 2007-04-16 Pfizer Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa.
US7091202B2 (en) 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
GB0517329D0 (en) 2005-08-25 2005-10-05 Merck Sharp & Dohme Stimulation of neurogenesis
CN101304993A (zh) 2005-11-07 2008-11-12 Irm责任有限公司 作为ppar调节剂的化合物和组合物
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
ES2555803T3 (es) 2006-10-23 2016-01-08 Cephalon, Inc. Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
EP2142551B1 (en) 2007-04-17 2015-10-14 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二(芳胺基)芳基化合物
SI2176231T1 (sl) 2007-07-20 2017-01-31 Nerviano Medical Sciences S.R.L. Substituirani indazolni derivati, aktivni kot kinazni inhibitorji
CA2932121A1 (en) 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
US20110038898A1 (en) 2008-03-13 2011-02-17 Shuichi Yada Dissolution properties of drug products containing olmesartan medoxomil
WO2010128324A1 (en) 2009-05-07 2010-11-11 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
EP3613729A1 (en) 2009-06-10 2020-02-26 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compounds
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
MY160110A (en) 2010-08-20 2017-02-28 Chugai Pharmaceutical Co Ltd Composition comprising tetracyclic compound
JP5006987B2 (ja) 2010-11-22 2012-08-22 中外製薬株式会社 4環性化合物を含む医薬
MX389105B (es) 2012-09-25 2025-03-20 Chugai Pharmaceutical Co Ltd Inhibidor de quinasas reordenadas durante la transfeccion (ret).
EP4397659A3 (en) 2014-04-25 2024-10-02 Chugai Seiyaku Kabushiki Kaisha Preparation containing tetracyclic compound at high dose
RU2016146119A (ru) 2014-04-25 2018-05-29 Чугаи Сейяку Кабусики Кайся Новый кристалл тетрациклического соединения
BR112016024421A2 (pt) 2014-06-18 2017-08-15 Chugai Pharmaceutical Co Ltd composição farmacêutica, cápsula e uso da composição farmacêutica
TWI831347B (zh) 2014-08-08 2024-02-01 日商中外製藥股份有限公司 包含4環性化合物的非晶質體之固體分散體及製劑
CN104402862B (zh) * 2014-11-12 2016-10-05 苏州明锐医药科技有限公司 艾立替尼的制备方法
US9573932B2 (en) 2015-03-02 2017-02-21 Yong Xu Synthesis of intermediates in the preparation of ALK inhibitor
WO2017073706A1 (ja) 2015-10-30 2017-05-04 中外製薬株式会社 ジヒドロナフト[2,3-b]ベンゾフラン誘導体
CN106928185B (zh) 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN106928184B (zh) 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN107033124B (zh) 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法

Also Published As

Publication number Publication date
HUE070227T2 (hu) 2025-05-28
HRP20250284T1 (hr) 2025-04-25
IL281079B2 (en) 2024-12-01
KR102635225B1 (ko) 2024-02-07
US11939322B2 (en) 2024-03-26
IL281079A (en) 2021-04-29
TW202024050A (zh) 2020-07-01
AU2019337018B2 (en) 2024-03-07
EP3848361A4 (en) 2022-06-15
EP3848361B1 (en) 2025-01-22
JPWO2020050241A1 (ja) 2021-08-30
CA3107270A1 (en) 2020-03-12
KR20210053890A (ko) 2021-05-12
JP7167171B2 (ja) 2022-11-08
BR112021001145A2 (pt) 2021-04-20
MX2021002311A (es) 2021-04-28
SG11202100983XA (en) 2021-03-30
US20220372025A1 (en) 2022-11-24
CN112585126A (zh) 2021-03-30
CN112585126B (zh) 2024-05-07
IL281079B1 (en) 2024-08-01
AU2019337018A1 (en) 2021-03-18
ES3010145T3 (en) 2025-04-01
TWI825163B (zh) 2023-12-11
AR116113A1 (es) 2021-03-31
WO2020050241A1 (ja) 2020-03-12
EP3848361A1 (en) 2021-07-14
EP3848361C0 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
PL3690969T3 (pl) Sposób wytwarzania w pełni roztworowego urządzenia oled
PL3666525T3 (pl) Sposób wytwarzania strukturyzowanej powierzchni
PL3490395T3 (pl) Sposób wytwarzania aerozolu
PL3709979T3 (pl) Sposób wytwarzania powlekanej kapsułki twardej
EP3594214A4 (en) COMPOUND POLYMORPH, RELATED PREPARATION PROCESS AND USE THEREOF
PL3848361T3 (pl) Sposób wytwarzania związku tetracyklicznego
PL3630738T3 (pl) Sposób wytwarzania ozanimodu
PL3942107T3 (pl) Sposób wytwarzania
PL4019485T3 (pl) Sposób wytwarzania pochodnych heterocyklidenoacetamidu
TWI800668B (zh) 晶片製造方法
PL3548473T3 (pl) Sposób wytwarzania hmf
PL4046129T3 (pl) Sposób wytwarzania
DK3668835T3 (da) Fremgangsmåde til fremstilling af en monothiocarbonatforbindelse
EP3819299A4 (en) Hypoxanthine compound
PL3640991T3 (pl) Sposób wytwarzania wyświetlacza OLED
GB2582844B (en) Method of assembling a structure
IL280904A (en) Method for manufacturing cyclopropane compound
PL3941902T3 (pl) Sposób wytwarzania chlorku trifluorometanosulfinylu
PL3726603T3 (pl) Sposób wytwarzania akumulatora
TWI799659B (zh) 玻璃物品的製造方法
TWI800658B (zh) 晶片製造方法
EP3848198A4 (en) LAMINATE PRODUCTION PROCESS
EP3373425A4 (en) METHOD FOR PRODUCING A LAMINATED CORE
PL3956293T3 (pl) Sposób wytwarzania cyjanooctanów
PL3956297T3 (pl) Sposób wytwarzania cyjanooctanów